Enhancement of all-trans-retinoic acid efficiency in granulocytic differentiation of HL-60 cells by incorporation into low density lipoprotein

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 1069-1075

  Gueddari, Naima ^a   Bobichon, Hélène ^a   Depierreux, Christiane ^a   Liautaud Roger, Françoise ^b   Duriez, Patrick ^c   Dufer, Jean ^a   Jardillier, Jean Claude ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b Institut J Godinot   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

ATRA LDL; Cell maturation; HL 60; LDL receptor

Indexed keywords

DAUNORUBICIN; DRUG CARRIER; LOW DENSITY LIPOPROTEIN RECEPTOR; RETINOIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; GRANULOCYTE; HUMAN; HUMAN CELL; IMAGE CYTOMETRY; PRIORITY JOURNAL;

EID: 0031762916     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.1069     Document Type: Article

References (32)

1. Collins SJ, Robertson KA and Mueller L: Retinoic acid-induced differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RARα). Mol Cell Biol 10: 2154-2163, 1990.
2. Breitman T, Selonick S and Collins S: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936-2940, 1980.
3. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L: All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical Results. Blood 76: 1704-1707, 1990.
4. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S and Degos L: All-trans-retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76: 1710-1717, 1990.
5. Warrel RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS and Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385-1393, 1991.
6. Agadir A, Comic C, Lefebvre P, Gourmel B, Balitrand N, Degos L and Chomienne C: Differential uptake of all-trans-retinoic acid by acute promyelocytic leukemic cells: evidence for its role in retinoic acid efficacy. Leukemia 9: 139-145, 1995.
7. Francis PA, Rigas JR, Muindi J, Kris MG, Young CW and Warrel RP: Modulation of all-trans-retinoic acid (RA) pharmaco-kinetics by a cytochrome P450 enzyme system inhibitor. Proc Am Soc Clin Oncol 11: 108-112, 1992.
8. Durand B, Saunders M, Leroy P, Leid M and Chambon P: All-trans and cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell 71: 73-85, 1992.
9. Cornic M, Delva L, Castaigne S, Lefebvre P, Balitrand N, Degos L and Chomienne C: In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relaps leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 8: 914-917, 1994.
10. Drach J, Lopez-Berestein G, McQueen TT, Andreeff M and Mehta K: Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53: 2100-2104, 1993.
11. Vitols S, Angelin B, Ericsson S, Gahrton G, Juliosson G, Masquelier M, Paul C, Peterson C, Rudling M, Soderberg-Reid K and Tidefeldt U: Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA 87: 2598-2602, 1990.
12. Filipowska D, Filipowski T, Morelowska B, Kazanowska W, Laudanski T, Lapinjoki S, Akerlund M and Breeze A: Treatment of cancer patients with low-density-lipoprotein delivery vehicle containing a cytotoxic drue. Cancer Chemother Pharmacol 29: 396-400, 1992.
13. Lundberg B and Suominen L: Preparation of biologically active analogs of serum low density lipoprotein. J Lipid Res 25: 550-558, 1984.
14. Vitols S, Söderberg-Reid K, Masquelier M, Sjöstrom B and Peterson C: Low-density lipoprotein for delivery of a waterinsoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. BrJ Cancer 62: 724-729, 1990.
15. De Smidt PC and van Berkel TJC: Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 50: 7476-7482, 1990.
16. Brousseau T, Clavey V, Bard JM and Fruchard JC: Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins and lipoprotein particles. Clin Chem 39: 960-964, 1993.
17. Samadi-Baboli M, Favre G, Canal P and Soula G: Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer 68: 319-326, 1993.
18. Gadde RR and Burton FW: Simple reversed-phase high-performance liquid chromatographic method for 13-cis-retinoic acid in serum. J Chromatogr 593: 41-46, 1992.
19. Bilheimer DW, Eisenberg S and Levy RI: The metabolism of very low density lipoproteins I. Preliminary in vitro and in vivo observation. Biochim Biophys Acta 260: 212-221, 1972.
20. Collins SJ, Ruscetti FW, Gallagher RE and Gallo RC: Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 149: 969-974, 1979.
21. Brugal G: Image analysis of microscopic preparations. Methods Achiev Exp Pathol 11: 1-33, 1984.
22. Hallouche F, Adams A, Hinton O, Surtees D, Wadehra V and Sherbet G: Discriminant analysis for classification of murine melanomas and human cervical epithelial cells. Anal Quant Cytol Histol 15: 50-63, 1993.
23. Bobichon H, Colin M, Depierreux C, Liautaud-Roger F and Jardillier JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J Exp Ther Oncol 1: 49-61, 1996.
24. Ho YK, Brown MS, Kayden HJ and Goldstein JL: Binding, internalization, and hydrolysis of low density lipoprotein in long-term lymphoid cell lines from a normal subject and a patient with homozygous familial hypercholesterolemia. J Exp Med 144: 444-455, 1976.
25. Bobichon H, Mayer P, Carpentier Y and Desoize B: HL-60 cells exhibit particuliar ultrastructural features during all-trans retinoic acid-induced apoptosis. Int J Oncol 12: 649-653, 1998.
26. Dufer J, Biako D, Joly P, Benoist H, Carpentier Y and. Desplaces A: Quantitative morphological aspect of granulocytic differentiation induced in HL-60 cells by dimethysulfoxide and retinoic acid. Leuk Res 13: 621-627, 1989.
27. Turgeon ML: Leukocytes: the granulocytic and monocytic series. In: Clinical Hematology, Theory and Procedures. 2nd edition. Little, Brown and Co., Boston, pp128-140, 1993.
28. Iwanik MJ, Shaw KV, Ledwith BJ, Yanovich S and Shaw JM: Preparation and interaction of a low-density lipoprotein: daunomycin complex with P388 leukemic cells. Cancer Res 44: 1206-1215, 1984.
29. Lundberg B: Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture. Cancer Chemother Pharmacol 29: 241-247, 1992.
30. Comic M, Del va L, Guidez F, Balitrand N, Degos L and Chomienne C: Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 52: 3329-3334, 1992.
31. Pittman RC, Attie AD, Carew TE and Steinberg D: Tissue sites of degradation of low density lipoprotein: application of a method for determining the fate of plasma proteins. Proc Natl Acad Sci USA 76: 5345-5349, 1979.
32. Hynds SA, Welsh J, Stewart JM, Jack A, Soukop M, McArdle CS, Calman KC, Packard CJ and Shepherd J: Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim Biophys Acta 795: 589-595, 1984.